Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 2/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPA | Q15257 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271198 | 0.88 | NR1H4 (0.38) | UBE2MDCUN1D1MAPTHTTPTGIR | |
| SCHEMBL4272537 | 0.87 | UBE2M (0.42) | UBE2MDCUN1D1PTGIRALDH1A1TSHR | |
| SCHEMBL4272601 | 0.87 | UBE2M (0.42) | UBE2MDCUN1D1PTGIRALDH1A1TSHR | |
| SCHEMBL13657717 | 0.85 | ATM (0.41) | UBE2MDCUN1D1PTGIRALDH1A1TSHR | |
| SCHEMBL27667591 | 0.83 | UBE2M (0.46) | UBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL4276126 | 0.80 | ALDH1A1 (0.42) | UBE2MDCUN1D1PTGIRALDH1A1 | |
| SCHEMBL4276122 | 0.80 | ALDH1A1 (0.42) | UBE2MDCUN1D1PTGIRALDH1A1 | |
| SCHEMBL4268261 | 0.80 | UBE2M (0.43) | UBE2MDCUN1D1PTGIRALDH1A1TSHR | |
| SCHEMBL4268265 | 0.80 | UBE2M (0.43) | UBE2MDCUN1D1PTGIRALDH1A1TSHR | |
| SCHEMBL4270761 | 0.79 | UBE2M (0.42) | UBE2MDCUN1D1PTGIRALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | claimed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | claimed |
| EP-1730099-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1730099-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092011-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | claimed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| EP-1730099-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1730099-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092011-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | UBE2M 2628/4885DCUN1D1 1388/4885MAPT 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.